Valkyrie Clinical Trials Inc

1. Boehringer Ingelheim Pharmaceuticals, Inc. $13,270,449 655 payments
2. AbbVie, Inc. $1,417,724 104 payments
3. Janssen Research & Development, LLC $1,395,934 63 payments
4. Genentech, Inc. $1,114,768 43 payments
5. Regeneron Pharmaceuticals, Inc. $1,091,475 83 payments
6. BioNTech SE $923,958 298 payments
7. Mirati Therapeutics, Inc. $608,102 106 payments
8. Amgen Inc. $459,421 4 payments
9. G1 Therapeutics, Inc. $388,630 227 payments
10. AstraZeneca Pharmaceuticals LP $163,010 1 payment

1. A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 $3,367,648 141 payments
2. Phase II study in SCLC and epNEC $2,413,976 2 payments
3. Phase I FIH study of BI 1810631 $2,136,507 2 payments
4. Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations $1,955,569 198 payments
5. Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours $1,459,077 150 payments
6. A Phase 1/2 Study of Regn7075 (Egfrxcd28 Costimulatory Bispecific Antibody) in Combination With Cemiplimab in Patients With Advanced Solid Tumors $1,091,475 83 payments
7. A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc $1,040,635 41 payments
8. A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL) $829,606 59 payments
9. Ph3 study of Pola R CHP Glofit vs PolaR CHP in 1L DLBCL $811,809 35 payments
10. DAREON-5: An open-label, multi-center Phase II dose selection trial of intravenous BI 764532, a DLL3-targeting T cell engager, in patients with relapsed/refractory extensive-stage small cell lung cancer and in patients with other relapsed/refractory neuroendocrine carcinomas $671,920 73 payments

1. Non-patient care $456,544 84 payments
2. Patient care $151,557 22 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.